PLEASANTON, Calif., April 18, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced the Veeva AI Partner Program to provide partners with the advanced technology and support needed to integrate Generative AI (GenAI) solutions seamlessly with Veeva Vault applications.
"Our customers are exploring GenAI solutions across many use cases as the technology evolves," said Tom Schwenger, Veeva president and chief customer officer. "The Veeva AI Partner Program provides access to critical technology to help partners develop GenAI solutions that integrate seamlessly with Veeva applications."
The Veeva AI Partner Program includes:
The Veeva AI Partner Program is part of Veeva's focused strategy to enable AI for the life sciences industry. The Vault Direct Data API and AI Partner Program enable customers and partners to more easily build AI applications that integrate seamlessly with Vault applications.
Companies can learn more about the Veeva AI Partner Program at Veeva Commercial Summit in Boston, May 7-8, or at veeva.com/AIPartnerProgram.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.
Contact: | |
Alison Borris |

| Last Trade: | US$290.64 |
| Daily Change: | -0.56 -0.19 |
| Daily Volume: | 410,867 |
| Market Cap: | US$47.640B |
October 16, 2025 October 14, 2025 September 22, 2025 September 02, 2025 August 28, 2025 | |

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load